OBJECTIVE: To characterize the Fas-Fas ligand system, a main apoptotic pathway, in transitional cell carcinoma (TCC) of the urinary bladder, by analysing the expression of Fas and Fas ligand (FasL) in TCC samples. MATERIALS AND METHODS: Archival paraffin-embedded tissues from 37 patients with TCC were analysed by immunohistochemistry to determine Fas and FasL expression. RESULTS: Fas and FasL were detected on the cell surface and cytoplasm of respectively 34 (92%) and all cases analysed. The expression of Fas and FasL did not differ with the cytological grade of TCC. CONCLUSION: The high expression of FasL in TCC, reported for the first time in the present study, suggests that FasL may contribute to the immune escape of TCC through killing Fas-bearing lymphocytes. Co-expression of Fas with FasL also suggests that TCC may have pathways resistant to Fas-mediated autocrine cell suicide.
OBJECTIVE: To characterize the Fas-Fas ligand system, a main apoptotic pathway, in transitional cell carcinoma (TCC) of the urinary bladder, by analysing the expression of Fas and Fas ligand (FasL) in TCC samples. MATERIALS AND METHODS: Archival paraffin-embedded tissues from 37 patients with TCC were analysed by immunohistochemistry to determine Fas and FasL expression. RESULTS:Fas and FasL were detected on the cell surface and cytoplasm of respectively 34 (92%) and all cases analysed. The expression of Fas and FasL did not differ with the cytological grade of TCC. CONCLUSION: The high expression of FasL in TCC, reported for the first time in the present study, suggests that FasL may contribute to the immune escape of TCC through killing Fas-bearing lymphocytes. Co-expression of Fas with FasL also suggests that TCC may have pathways resistant to Fas-mediated autocrine cell suicide.
Authors: F G Perabo; S Kamp; D Schmidt; H Lindner; G Steiner; R H Mattes; A Wirger; K Pegelow; P Albers; E C Kohn; A von Ruecker; S C Mueller Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640
Authors: K Yamana; V Bilim; N Hara; T Kasahara; T Itoi; R Maruyama; T Nishiyama; K Takahashi; Y Tomita Journal: Br J Cancer Date: 2005-09-05 Impact factor: 7.640